Ilmarinen Mutual Pension Insurance Co Sells 27,000 Shares of Abbott Laboratories $ABT

Ilmarinen Mutual Pension Insurance Co lowered its stake in Abbott Laboratories (NYSE:ABT) by 8.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 280,500 shares of the healthcare product maker’s stock after selling 27,000 shares during the quarter. Ilmarinen Mutual Pension Insurance Co’s holdings in Abbott Laboratories were worth $35,144,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in ABT. Vanguard Group Inc. increased its position in Abbott Laboratories by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock worth $21,995,501,000 after purchasing an additional 2,402,408 shares in the last quarter. Capital International Investors boosted its position in Abbott Laboratories by 2.5% in the third quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock valued at $8,251,974,000 after buying an additional 1,478,076 shares in the last quarter. Invesco Ltd. boosted its position in Abbott Laboratories by 51.0% in the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock valued at $1,868,718,000 after buying an additional 4,713,135 shares in the last quarter. Ameriprise Financial Inc. boosted its position in Abbott Laboratories by 3.8% in the third quarter. Ameriprise Financial Inc. now owns 13,500,829 shares of the healthcare product maker’s stock valued at $1,804,050,000 after buying an additional 499,351 shares in the last quarter. Finally, Legal & General Group Plc boosted its position in Abbott Laboratories by 7.2% in the third quarter. Legal & General Group Plc now owns 12,900,318 shares of the healthcare product maker’s stock valued at $1,727,869,000 after buying an additional 864,531 shares in the last quarter. 75.18% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Mizuho cut their target price on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a research report on Friday, April 17th. Benchmark cut their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Citigroup cut their target price on shares of Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Evercore cut their target price on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Finally, Bank of America cut their target price on shares of Abbott Laboratories from $150.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $119.09.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $86.19 on Friday. The firm has a market cap of $150.13 billion, a PE ratio of 24.14, a price-to-earnings-growth ratio of 1.43 and a beta of 0.65. The firm’s fifty day moving average is $94.92 and its 200-day moving average is $110.87. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $139.06.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. The company had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. Abbott Laboratories’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Sell-side analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current year.

Insider Transactions at Abbott Laboratories

In other news, Director Daniel J. Starks bought 10,000 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The shares were acquired at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the acquisition, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Eric Shroff sold 709 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the transaction, the senior vice president owned 39,164 shares in the company, valued at approximately $4,526,575.12. The trade was a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 3,055 shares of company stock worth $353,097. Company insiders own 0.46% of the company’s stock.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott secured CE Mark approval in Europe for Libre Duo, the world’s first dual glucose-ketone sensing technology for diabetes care, which could broaden its addressable market and strengthen its diabetes device franchise. Article Title
• Positive Sentiment: The American Cancer Society reaffirmed Abbott’s noninvasive colorectal cancer screening products, Cologuard and Cologuard Plus, as preferred options for average-risk adults, supporting demand for the company’s screening portfolio. Article Title
• Positive Sentiment: Abbott also won FDA and EU clearance for its AI-powered Ultreon 3.0 software, which helps guide artery stent placement and could support growth in its cardiovascular business. Article Title
• Neutral Sentiment: Analyst-focused articles reiterated that Wall Street remains broadly bullish on Abbott, and Goldman Sachs maintained a Buy rating even after trimming its price target to $113 from $121. Article Title
• Neutral Sentiment: Commentary on Abbott’s diagnostics unit pointed to a mixed quarter, with Core Lab growth offset by China weakness and softer respiratory testing demand, suggesting uneven near-term performance in the segment. Article Title
• Negative Sentiment: Some market coverage noted that Abbott’s shares fell in a recent session despite a broader market uptick, reflecting lingering pressure even as fundamental news flow turns more favorable. Article Title

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.